A key objective in personalized oncology is identifying the drug-sensitivity profile of a patient’s cancer to a wide spectrum of different drugs. In this project, a new method will be developed for the rapid identification of the drug-sensitivity profile of a specific type of ovarian cancer to numerous drugs. The multidisciplinary team brings together scientists from diverse fields, including nanoparticles, nanochemistry, cancer biology, pathology, and systems biology. Using smart, stimulus-responsive nanoparticles, the team will simultaneously screen the ability of multiple drugs to kill cancer cells in vivo.